FinnMedi Oy Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4
Founded: Tampere Finland (1989)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2008
NCT00596791
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Clinical Trial Center, FinnMedi Oy | FinnMedi Oy | Finn-Medi Research, Finland | FINN-MEDI Research Oy

Active Ingredients

Drugs in Phase 4 Trials (1)

tafluprost (zioptan) (2 trials)

Drugs in Phase 2 Trials (1)

latiglutenase (2 trials)

Drugs in Phase 1 Trials (1)

cis-urocanic acid (1 trial)

Drugs in Other Trials (2)

barley starch (1 trial)

maize starch (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypertension (Phase 4)

Ocular Hypertension (Phase 4)

Signs and Symptoms (Phase 4)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 5